Skip to main content

Table 2 Estimated Reporting Rate of All Malignancies and Lymphoma per 100 Patient-years (PY) of Etanercept Exposure

From: Summary of worldwide pediatric malignancies reported after exposure to etanercept

  4-17 years 18-22 years
  Worldwide US Worldwide US
Estimated exposure to etanercept (PY) through July 2009 49,716 33,409 33,887 22,349
All malignancies (rate/100 PY) 0.020 0.015 0.024* 0.013*
Lymphoma (rate/100 PY) 0.010 0.009 0.006* 0.004*
  1. *Calculated reporting rate for those age 18-22 years includes only cases with exposure prior to age 19 and does not includes cases with first etanercept exposure at age 19-22.
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096